Jonathan Waltman, MD
Cardiovascular Disease · Lebanon, NHNPI 1639181654
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Johnson & Johnson at 27.7% of the total. Reporting peaked in 2019 at $920 and has fallen 98.1% since, to $17 in 2024.
Across 141 payments — averaging $13.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$521
- AstraZeneca$264
- Abbott$162
- Novartis$108
- Pfizer$105
- Chiesi USA, Inc.$87
- plus $633 from 20 others
Across 14 payments — averaging $11,917 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$163K
- Sanofi US Services Inc.$4K
What the payments were for
- Food & beverage$1,86699%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 62 | $521 |
| AstraZeneca | 13 | $264 |
| Abbott | 7 | $162 |
| Novartis | 7 | $108 |
| Pfizer | 7 | $105 |
| Chiesi USA, Inc. | 6 | $87 |
| Sanofi-aventis U.S. LLC | 5 | $83 |
| Amgen | 5 | $73 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $66 |
| Lundbeck LLC | 4 | $57 |
| Amarin Pharma, Inc. | 3 | $57 |
| Philips North America LLC | 1 | $54 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Medtronic | 2 | $39 |
| Novo Nordisk | 2 | $25 |
| CSL Behring | 1 | $21 |
| W. L. Gore & Associates, Inc. | 1 | $17 |
| Cardinal Health 200 LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Gilead | 1 | $13 |
| Boehringer Ingelheim | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Verge Medical, Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
| Cardiovascular Systems Inc. | 1 | $7 |
| Bardy Diagnostics, Inc. | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$111
How this compares
$1,880 in reported general payments places this provider in the 65th percentile of 112 cardiovascular disease providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 454 | $465,561 |
| XareltoRivaroxaban | 97 | $104,998 |
| Repatha SureclickEvolocumab | 69 | $81,549 |
| JardianceEmpagliflozin | 73 | $78,550 |
| EntrestoSacubitril/Valsartan | 34 | $42,493 |
| Praluent PenAlirocumab | 42 | $35,439 |
| Repatha SyringeEvolocumab | 14 | $16,624 |
| FarxigaDapagliflozin Propanediol | 13 | $11,789 |
| Metoprolol Succinate | 507 | $7,398 |
| Ezetimibe | 166 | $6,030 |
| Rosuvastatin Calcium | 308 | $5,055 |
| Atorvastatin Calcium | 297 | $4,388 |
| Losartan Potassium | 293 | $2,552 |
| Ranolazine ErRanolazine | 18 | $2,476 |
| Spironolactone | 254 | $2,122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $105 | $465,561454 claims |
| Johnson & JohnsonXarelto | $521 | $104,99897 claims |
| Boehringer IngelheimJardiance | $13 | $78,55073 claims |
| NovartisEntresto | $108 | $42,49334 claims |
| AstraZenecaFarxiga | $264 | $11,78913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 112 cardiovascular disease providers in New Hampshire.
Other cardiovascular disease in Lebanon
- Kevin KwakuLebanon$79K
- Michael YoungLebanon$53K
- Merle MyersonLebanon$15K
- Ian GilchristLebanon$13K
- Robert DangeloLebanon$10K
- Rumman SyedLebanon$9K
- Mohammadtokir MujtabaLebanon$8K
- Lauren Gilstrap MilleyLebanon$5K
- Fernando Contreras-ValdesLebanon$5K
- David MinLebanon$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.